Evotec entered an exclusive collaboration with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in several undisclosed disease areas for internal and external drug discovery projects.
According to the company, this alliance expands Evotec's existing drug discovery platform with access to a broad range of complementary and highly innovative platforms and capabilities to progress projects and provide additional capabilities for customers and partners of both organizations. The deal follows the joint decision of Evotec, Fraunhofer-Gesellschaft, and the City of Hamburg to integrate the European ScreeningPort into the IME thereby forming the first Fraunhofer life science institution in the city.
“We are looking forward to partner with Fraunhofer IME and are excited about the potential of this alliance,” said Dr. Werner Lanthaler, CEO of Evotec. “The IME has an impressive track record for product development and provides an ideal basis for collaborating with one of the strongest science organizations in Germany and beyond. This adds another footprint in Europe of our EVT Innovate programs as we have with U.S. based academic institutions.”
“Evotec's medicinal chemistry and expertise will add value to our own, our joint and our partner's programs,” said Rainer Fischer, Ph.D., senior executive director at the Fraunhofer IME.